| Article Access Statistics|
| Viewed||2260 |
| Printed||119 |
| Emailed||1 |
| PDF Downloaded||167 |
| Comments ||[Add] |
| Cited by others ||1 |
Click on image for details.
| RESEARCH ARTICLE
|Year : 2011 | Volume
| Issue : 4 | Page : 385-388
Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients
Paraskevi F Katsakiori1, Eirini P Papapetrou2, Dimitrios S Goumenos3, George C Nikiforidis4, Christodoulos S Flordellis1
1 Department of Pharmacology, School of Medicine, University of Patras, Rion, Greece
2 Center for Cell Engineering, Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY 10065, USA
3 Department of Internal Medicine-Nephrology, School of Medicine, University of Patras, Rion, Greece
4 Department of Medical Physics, School of Medicine, University of Patras, Rion, Greece
Objectives: Atherosclerosis is a significant factor affecting long-term outcome in renal transplant recipients. Studies have been conducted to determine the pharmacogenomic pathways involved in statin efficacy, efficiency, and adverse effect likelihood. However, little is known about the influence of statins on tacrolimus kinetics. The aim of this study was to investigate possible pharmacological interactions between tacrolimus and statins in CYP3A5 non-expressors, renal transplant recipients.
Materials and Methods: Twenty-four patients, treated with tacrolimus (n=24), methylprednisolone (n=24), and mycophenolate mofetil (n=19)/azathioprine (n=1)/everolimus (n=4), participated in the study. After an observation time of 112±36 days, statins, namely, atorvastatin (n=12), simvastatin (n=8), pravastatin (n=2), or fluvastatin (n=2), were administered for additional 101±34 days. DNA was extracted from whole blood sample and polymerase chain reaction followed by restriction fragment length polymorphism analysis was used for CYP3A5 genotyping. Student's t-test and Mann-Whitney test were used to test the significance of difference in variables that passed or did not pass Kolmogorov's normality test, respectively.
Results: No statistically significant difference was observed in tacrolimus daily dose, concentration, concentration/dose ratio, and volume of distribution before and during the administration of statins. Statistically significant decrease in serum cholesterol was observed after initiation of statins. Renal and hepatic function remained unchanged and no skeletal muscle abnormalities were reported.
Conclusions: The results of this study show that tacrolimus and statins do not interact in terms of efficacy, efficiency, and adverse effect likelihood. No significant clinical interaction or effect was observed, even with the use of atorvastatin or simvastatin, which are metabolized by CYP3A4 such as tacrolimus.
Paraskevi F Katsakiori
Department of Pharmacology, School of Medicine, University of Patras, Rion
Source of Support: None, Conflict of Interest: None
[FULL TEXT] [PDF]*